Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors

Oncotarget
J CasaosNicolas Skuli

Abstract

Atypical teratoid/rhabdoid tumors (AT/RT) are highly aggressive, malignant tumors and are the most common malignant brain tumor in children under 6 months of age. Currently, there is no standard treatment for AT/RT. Recent studies have reported potential anti-tumoral properties of ribavirin, a guanosine analog and anti-viral molecule approved by the Food and Drug Administration for treatment of hepatitis C. We previously demonstrated that ribavirin inhibited glioma cell growthin vitroandin vivo. Based on these results and the fact that no pre-clinical model of ribavirin in AT/RT exists, we decided to investigate the effect of ribavirin on several human AT/RT cell lines (BT12, BT16, and BT37) bothin vitroandin vivo. We provide evidence that ribavirin has a significant impact on AT/RT cell growth and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E and/or EZH2 pathways. Interestingly, using scratch wound and transwell Boyden chamber assays, we observed that ribavirin also impairs AT/RT cell migration, invasion, and adhesion. Finally, we demonstrate that ribavirin significantly improves the survival of mice orthotopically implanted with BT12 cells. Our work establishes that ribavirin is effec...Continue Reading

References

May 1, 1987·Virology·L M ScheidelV Stollar
May 1, 1987·Infection Control : IC·M Eggleston
Aug 15, 1996·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·P HarvieM G Bergeron
Sep 12, 2000·European Journal of Pharmacology·S ValléeS Champion
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·M HosoyaH Suzuki
Nov 20, 2002·Mutation Research·K NarayanaK P Seetharama Rao
Oct 14, 2004·Drug and Chemical Toxicology·Soheila DadgostariDomenico Vitarella
Dec 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Alex KentsisKatherine L B Borden
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 17, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·Xin GuMarjorie Fowler
Oct 28, 2005·RNA·Alex KentsisKatherine L B Borden
Dec 16, 2006·Current Medicinal Chemistry·Stefan RussmannGiuseppe Palasciano
Oct 19, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shannon Reagan-ShawNihal Ahmad
Feb 12, 2009·Molecular Cancer Therapeutics·Gary L GalliaGregory J Riggins
Mar 18, 2010·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Alexander C Zambon
Jul 16, 2010·Leukemia & Lymphoma·Katherine L B Borden, Biljana Culjkovic-Kraljacic
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Filippa PetterssonWilson H Miller
Mar 9, 2012·Cancer Research·Thomas J HaymanPhilip J Tofilon
Mar 20, 2012·The Journal of Clinical Investigation·Nicolas SkuliM Celeste Simon
Apr 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sarah K KnutsonHeike Keilhack
Feb 1, 2014·International Journal of Molecular Sciences·Julie SesenNicolas Skuli
Feb 28, 2014·Journal of Neuro-oncology·Simone Treiger SredniTadanori Tomita
Nov 5, 2014·Oncology Letters·Akiyoshi OginoYoichi Katayama
Jan 13, 2015·Journal of Neuropathology and Experimental Neurology·Harpreet KaurEric H Raabe
Mar 5, 2015·Oncology Reports·Erick De la Cruz-HernandezAlfonso Dueñas-Gonzalez
Mar 7, 2015·Nature Reviews. Drug Discovery·Mamatha BhatIvan Topisirovic
Jul 8, 2015·Journal of Cancer Research and Therapeutics·Silvina M Richard, Veronica L Martinez Marignac
Jan 26, 2016·World Journal of Hepatology·Véronique Loustaud-RattiPaul Carrier
Jun 10, 2016·British Journal of Cancer·Rebecca A Millican-SlaterThomas A Hughes
Jul 6, 2016·Pharmacological Reports : PR·Sapna SharmaMilee Agarwal
Nov 8, 2016·Experimental Cell Research·Andjelka M IsakovicAleksandra Isakovic

❮ Previous
Next ❯

Citations

Mar 5, 2020·Neuro-oncology·Lindsey M HoffmanAnnie Huang
May 6, 2020·Pharmaceutics·Filipa Moreira-SilvaCarmen Jerónimo
Sep 28, 2020·FEBS Open Bio·Vicente Morales-GarciaErick de la Cruz-Hernandez
Jul 3, 2019·Molecular Cancer Therapeutics·Joshua CasaosNicolas Skuli
Dec 15, 2020·Frontiers in Oncology·Michel Montalvo-CasimiroLuis A Herrera
Feb 6, 2021·Journal of Neurosurgery. Pediatrics·Sakibul HuqBetty M Tyler

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
xenograft

Clinical Trials Mentioned

NCT02109744
NCT02073838
NCT01268579
NCT01056757

Software Mentioned

ImageJ
FlowJo
Image J

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.